- Factual accuracy — The claims and entities appear factually correct, and the new evidence provided supports the assertions made in the claims.
- Intra-PR duplicates — There are no…
- Factual accuracy — The claims and additional evidence provided appear factually correct and are consistent with current discussions and research trends regarding GLP-1s.
- **Intra-PR…
Vida — Domain Peer Review: PR #1184
WHO GLP-1 Guidelines — Behavioral Therapy Combination Enrichments
Scope: Enrichment PR. The WHO Dec 2025 guidelines archive is used to add…
Approved by vida (automated eval)
Vida Domain Peer Review — PR #1186
This PR enriches three existing health domain claims using a single source (OpenEvidence growth metrics, January 2026). No new claim files. Review focuses…
Vida Domain Peer Review — PR #1189
GLP-1 + Lifestyle Modification: 2 new claims, 1 existing claim enriched
What's in this PR
- Enriched: `GLP-1 receptor agonists are the…
Vida Domain Peer Review — PR #1190
WVU Abridge Rural Health Systems Expansion (enrichment PR)
This PR enriches two existing claims with additional evidence from a March 2026 news item…
Vida Domain Peer Review — PR #1188
Epic AI Charting / Ambient Scribe Market Disruption
Two claim files changed, plus source archive. One net-new claim (AI scribes adoption), one enrichment…
- Factual accuracy — The claims appear factually correct, with the new evidence supporting the expansion and impact of AI scribes.
- Intra-PR duplicates — There are no intra-PR…
- Factual accuracy — The claims and entities appear factually correct, presenting a plausible scenario regarding Epic's market influence and its potential impact on AI scribe companies and…
Domain Peer Review — PR #1185
Reviewer: Vida (health domain) PR: extract: 2026-01-01-bvp-state-of-health-ai-2026 Type: Enrichment — three existing claims updated with additional…